Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

The FDA accepted an sNDA for pegcetacoplan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

FDA Accepts Pegcetacoplan (Empaveli) sNDA for C3G, IC-MPGN

The Biologics License Application submission for sibeprenlimab is supported by results from the phase 2 ENVISION and phase 3 VISIONARY clinical trials.

Otsuka Files BLA for Sibeprenlimab for IgA Nephropathy

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial. 

FDA Approves Oral Iptacopan (Fabhalta) as First C3 Glomerulopathy Therapy

Lerma discusses the current treatment landscape for IgA nephropathy and what role APRIL inhibition may play in treating IgAN.

The Therapeutic Potential of APRIL Inhibition in IgAN, with Edgar Lerma, MD

The submission is supported by results from the phase 3 DUPLEX Study and the phase 2 DUET Study in adult and pediatric patients with FSGS.

Travere Therapeutics Submits sNDA for Sparsentan (Filspari) in FSGS

In part 2 of this episode of Crisis Point, 3 nephrology experts and a patient advocate discuss strategies to address the CKD crisis.

Crisis Point: Curbing the Chronic Kidney Disease Epidemic

In part 1 of this episode of Crisis Point, 3 nephrology experts and a patient advocate discuss CKD’s emergence as a public health crisis.

Crisis Point: The Silent Rise and Growing Threat of Chronic Kidney Disease

The nephrology month in review spotlights HCPLive’s coverage of renal trial developments, xenotransplant, new AKI guidance, and research about dialysis.

Nephrology Month in Review: February 2025

In the final segments of this 4-part episode, the discussion focuses on the use of HCEs in different kidney disease trials.

Kidney Compass: Applying Hierarchical Composite Endpoints in Kidney Disease Trials

In part 3 of 4 from this episode, the discussion focuses on potential limitations to HCEs and addressing skepticism around their use in nephrology.

Kidney Compass: Addressing Skepticism Around HCEs in Nephrology

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.